Boehringer Ingelheim Corporation Release: GLORIATM-AF Registry Program Investigating Use of Antithrombotic Therapy in 56,000 Patients with Atrial Fibrillation at Risk of Stroke Announced  
4/20/2012 10:48:41 AM

DUBAI, United Arab Emirates--(BUSINESS WIRE)--Boehringer Ingelheim announced today the launch of the GLORIATM-AF Registry Program, which is set to become the largest worldwide registry with the aim of understanding the long-term use of oral antithrombotic therapy in the prevention of non-valvular atrial fibrillation (AF)-related stroke in a real-world setting.